Kegg Pathway: Tight junction

KEGG ID: 04530

Reference Diagram

KEGG Diagram for Tight junction

Rat

There are 121 IPI Records from this pathway found in Rattus norvegicus.

Location of Tight junction proteins on Rat Genome

IPI Record Position
1: Actb 12:12047070-12050051
2: Actg1 10:109773489-109777655
3: Actn1 6:103110009-103282917
4: Actn2_predicted 17:68670924-68773261
5: Actn3 1:207475569-207492267
6: Actn4 1:84000723-84073767
7: Af6 1:48827689-48911351
8: Akt1 6:137640482-137657552
9: Akt2 1:82686233-82726544
10: Akt3 13:92807672-92924984
11: Amotl1_predicted 8:11295529-11394851
12: Ash1l_predicted 2:181030824-181149743
13: Cask X:20910960-21250869
14: Catna1 18:27629915-27769375
15: Cdc42 5:156106131-156143040
16: Cdk4 7:67016944-67018905
17: Cgn_predicted 2:189645090-189670491
18: Cldn1 11:76473654-76488815
19: Cldn10_predicted 15:103699492-103793404
20: Cldn11 2:116626421-116639732
21: Cldn14 11:34142138-34151928
22: Cldn15_predicted 12:20823572-20844183
23: Cldn16 11:76314467-76333750
24: Cldn17_predicted 11:28370367-28371041
25: Cldn19 5:139838014-139842621
26: Cldn22_predicted 16:47625078-47625740
27: Cldn23 16:60109161-60110885
28: Cldn2_predicted X:127546208-127547889
29: Cldn3 :-
30: Cldn4 12:22816134-22817932
31: Cldn5 :-
32: Cldn6_predicted 10:12945822-12946518
33: Cldn8 11:28421182-28421859
34: Cldn9 10:12947838-12948491
35: Crb3 :-
36: Csda 4:169076517-169099854
37: Csnk2a1 3:142588572-142609301
38: Csnk2a2_predicted 19:10015349-10049896
39: Csnk2b 20:3764565-3768982
40: Ctnna2_predicted 4:110776309-111694975
41: Ctnnb1 8:125978161-125987670
42: Cttn 1:204867012-204894931
43: Epb4.1l1 3:146876457-146941870
44: Epb4.1l3 9:108185553-108426942
45: Exoc3 1:29735289-29970088
46: Exoc4 4:60406942-61283713
47: F11r 13:87369918-87393508
48: Gnai1 4:12489156-12493730
49: Gnai2 8:112861952-112882599
50: Gnai3 2:203668275-203706229
51: Hcls1 11:65620189-65641279
52: Hint1 :-
53: Hras 1:201385708-201388983
54: IPI00765011 :-
55: Jam2 :-
56: Jam3 8:26697127-26758579
57: Kras 4:182869242-182895106
58: Llgl1 10:46845810-46859268
59: LOC304000 11:36698623-36755559
60: LOC315953 8:104564145-104586332
61: Magi2 4:9949893-11441166
62: Magi3 2:199247903-199448518
63: Mpdz 5:100010136-100146625
64: Mpp5_predicted 6:101367516-101474173
65: Mras 8:104244660-104300504
66: Myh10 10:55445288-55576098
67: Myh13 10:54083412-54103099
68: Myh14 1:95081948-95146455
69: Myh2 10:53866823-53892138
70: Myh3 10:53776858-53800677
71: Myh4 10:53934663-53955419
72: Myh6 15:33044506-33068098
73: Myh7 15:33073619-33094587
74: Myh7b_predicted 3:146115456-146142361
75: Myh8 10:53973711-54002438
76: Myh9 7:115681444-115732774
77: Myl2 12:35653817-35663865
78: Myl7_predicted 14:86568143-86570932
79: Myl9_predicted 3:147177777-147193863
80: Mylpf 1:186472955-186474466
81: Nras 2:198292616-198302308
82: Pard3 19:57016001-57601905
83: Pard6a 19:35533934-35535711
84: Pard6b_predicted 3:159230179-159251250
85: Pard6g_predicted 18:76942285-77007923
86: Ppp2ca 10:37621256-37641006
87: Ppp2cb 16:62330513-62351968
88: Ppp2r1a 1:58442220-58461462
89: Ppp2r2a 15:46545988-46603956
90: Ppp2r2b 18:35866177-36318168
91: Ppp2r2c 14:79436062-79515914
92: Ppp2r2d 1:198640963-198674516
93: Prkca 10:97361597-97625118
94: Prkcb1 1:181118102-181459480
95: Prkcc 1:64145733-64172745
96: Prkcd 16:5954206-6030380
97: Prkce 6:9631428-10097023
98: Prkch 6:96069179-96281792
99: Prkci 2:116741675-116800916
100: PRKCQ 17:78485934-78631039
101: Prkcz 5:172062560-172095240
102: Pten 1:236771027-236837261
103: Rab13 2:182460998-182465393
104: Rab3b 5:130224124-130283668
105: RGD1559455_predicted 20:24686070-25040014
106: RGD1561394_predicted 3:54755067-54914353
107: RGD1562230_predicted 20:25900952-26268772
108: RGD1564762_predicted 5:150780470-150908888
109: RGD1565362_predicted 5:118820543-119130533
110: RGD1565978_predicted 9:110171418-110186247
111: Rhoa :-
112: Rras2 1:172026260-172097710
113: Rras_predicted 1:95490697-95495452
114: Spna2 3:8956380-9021833
115: Src 3:148157256-148170524
116: Sympk 1:78377926-78407568
117: Tjap1_predicted 9:10261994-10288192
118: Tjp1_predicted 1:119686175-119750533
119: Tjp3_predicted 7:9919331-9929982
120: Vapa 9:104339039-104368908
121: Yes1 9:112516842-112563988

Mouse

There are 121 IPI Records from this pathway found in Mus musculus.

Location of Tight junction proteins on Mouse Genome

IPI Record Position
1: A2AGU5_MOUSE :-
2: A2ANA3_MOUSE X:123188775-123189883
3: A2AQP0_MOUSE 2:155303099-155325492
4: Actb 5:143168256-143171864
5: Actg1 11:120161781-120164582
6: Actn1 12:81086385-81179156
7: Actn2 13:12323759-12395065
8: Actn3 19:4861223-4877884
9: Actn4 7:28602011-28671040
10: Akt1 :-
11: Akt2 7:27300516-27348213
12: Akt3 1:178862039-178967772
13: Ash1l 3:89051739-89165302
14: B230120H23Rik 2:72086605-72243269
15: Cask X:12678006-13003515
16: Cdc42 4:136591778-136629755
17: Cdk4 10:126466564-126470344
18: Cldn1 16:26272000-26287188
19: Cldn10a 14:117701416-117788616
20: Cldn11 3:31340824-31355199
21: Cldn13 5:135199324-135199956
22: Cldn14 16:93807573-93897377
23: Cldn15 5:137252496-137260467
24: Cldn16 16:26378509-26398125
25: Cldn17 16:88395024-88395698
26: Cldn18 9:99500151-99519367
27: Cldn19 4:118753401-118757787
28: Cldn2 X:135147192-135157748
29: Cldn23 8:37293959-37294849
30: Cldn3 5:135270841-135272099
31: Cldn4 5:135230740-135231372
32: Cldn5 16:18690410-18691823
33: Cldn6 17:23406987-23410062
34: Cldn7 11:69781696-69784073
35: Cldn8 16:88451217-88451894
36: Cldn9 17:23410618-23411271
37: Crb3 17:56747348-56751067
38: Csda 6:131330551-131354143
39: Csnk2a1 2:151918326-151973281
40: Csnk2a2 8:98337108-98377956
41: Csnk2b 17:34724251-34729503
42: Ctnna1 18:35244863-35380747
43: Ctnna2 6:76812059-77775094
44: Ctnna3 10:62899394-64398190
45: Ctnnb1 9:120782173-120809205
46: Cttn 7:144245125-144280399
47: Epb4.1 4:131195505-131347350
48: Epb4.1l1 2:156112350-156234655
49: Epb4.1l2 10:25049323-25212930
50: Epb4.1l3 17:69061712-69194891
51: Exoc3 13:74635807-74674702
52: Exoc4 6:33179286-33903101
53: F11r 1:173274236-173301268
54: Gnai1 5:17776959-17872237
55: Gnai2 9:107472231-107493318
56: Gnai3 3:108235337-108274202
57: Hcls1 16:36856526-36881988
58: Hras1 7:141040427-141045314
59: Igsf5 16:96466704-96508938
60: Inadl 4:97887844-98211621
61: IPI00343257 18:46480724-46482298
62: IPI00673975 16:48977103-49117784
63: IPI00678029 :-
64: Jam2 16:84657025-84707359
65: Jam3 9:26846831-26904839
66: Kras 6:145173866-145207390
67: Llgl1 11:60515918-60530375
68: Llgl2 11:115640139-115671870
69: Magi1 6:93643711-94248785
70: Magi3 3:104144030-104349088
71: Mpdz 4:80749736-80914038
72: Mpp5 12:79667764-79759426
73: Mras 9:99197332-99235248
74: Myh1 11:67016297-67040772
75: Myh10 11:68508129-68632825
76: Myh11 16:14108110-14204950
77: Myh13 11:67143298-67187261
78: Myh14 7:44473872-44538885
79: Myh2 11:66987261-67013709
80: Myh3 11:66896194-66918361
81: Myh4 11:67054224-67076641
82: Myh6 14:53896562-53919669
83: Myh7 14:53924897-53948705
84: Myh8 11:67093319-67124829
85: Myh9 15:77587843-77669360
86: Myl2 5:122362366-122367386
87: Myl7 11:5796639-5798785
88: Mylc2b 17:70878820-70895373
89: Mylc2pl 5:136978805-136985721
90: Mylpf 7:127004009-127005343
91: Nras 3:103187290-103196967
92: Ocln 13:101597574-101652864
93: Pard3 8:129950335-130496920
94: Pard6a 8:108590812-108592594
95: Pard6b 2:167772490-167790415
96: Pard6g 18:80209011-80281439
97: Ppm1j 3:104909112-104914004
98: Ppp2ca 11:51942247-51966172
99: Ppp2cb 8:35065560-35085738
100: Ppp2r1a 17:20650151-20670602
101: Ppp2r1b 9:50609165-50646459
102: Ppp2r2b 18:42763405-43184571
103: Ppp2r2c 5:37156819-37243329
104: Ppp2r2d 7:138684702-138721397
105: Ppp2r3a :-
106: Ppp2r4 2:30238059-30269813
107: Prkca 11:107754338-108159844
108: Prkcb1 7:122080445-122419803
109: Prkcc :-
110: Prkcd 14:29424378-29439321
111: Prkce 17:86076111-86563725
112: Prkch 12:74503879-74697023
113: Prkci 3:31186625-31243615
114: Prkcq 2:11090235-11219079
115: Prkcz 4:154103920-154205191
116: Pten 19:32823574-32892157
117: Rab13 3:90306718-90311896
118: Rab3b 4:108388240-108438745
119: Rhoa 9:108164298-108196026
120: Rras 7:44886032-44889683
121: Rras2 7:113837969-113908962
122: Spna2 2:29787686-29853457
123: Spnb2 11:29999722-30168144
124: Src 2:157115730-157163279
125: Sympk 7:18182954-18213134
126: Tjap1 17:45721457-45746594
127: Tjp1 7:65175115-65250189
128: Tjp2 19:24161608-24292051
129: Tjp3 10:80676336-80694363
130: Vapa 17:65479596-65513084
131: Yes1 5:32887814-32963638

Human

There are 121 IPI Records from this pathway found in Homo sapiens.

Location of Tight junction proteins on Human Genome

IPI Record Position
1: ACTB 7:5533313-5535814
2: ACTN1 14:68410793-68515747
3: ACTN2 1:234916431-234994554
4: ACTN3 11:66070967-66087373
5: ACTN4 19:43830167-43913010
6: AKT1 14:104306734-104333125
7: AKT2 19:45430084-45483036
8: AKT3 1:241718158-242080053
9: AMOTL1 11:94141185-94250990
10: ASH1L 1:153571683-153799108
11: CASK X:41259131-41667660
12: CDC42 1:22235157-22292024
13: CDK4 12:56428272-56432431
14: CGN 1:149750497-149777792
15: CLDN1 3:191506197-191522909
16: CLDN10 13:94883859-95030014
17: CLDN11 3:171619359-171634577
18: CLDN14 21:36754793-36870737
19: CLDN16 3:191588535-191611027
20: CLDN17 21:30460132-30460806
21: CLDN18 3:139200348-139235184
22: CLDN19 1:42971351-42978512
23: CLDN2 X:106030050-106060747
24: CLDN20 6:155626839-155639374
25: CLDN22 4:184477703-184478365
26: CLDN23 8:8597319-8598197
27: CLDN3 7:72821653-72822315
28: CLDN4 7:72880010-72884950
29: CLDN5 22:17890550-17895068
30: CLDN6 16:3004715-3008187
31: CLDN7 17:7103390-7107236
32: CLDN8 21:30508196-30510223
33: CLDN9 16:3002458-3004507
34: CRB3 19:6414788-6418225
35: CSDA 12:10742956-10767171
36: CSNK2A1 20:411340-472482
37: CSNK2A2 16:56749320-56789283
38: CTNNA1 5:138117006-138298619
39: CTNNA2 2:79732191-80729415
40: CTNNA3 10:67349725-69125933
41: CTNNB1 3:41216004-41256938
42: CTTN 11:69922292-69960337
43: EPB41 1:29086215-29319545
44: EPB41L1 20:34142840-34284135
45: EPB41L2 6:131202180-131426058
46: EPB41L3 18:5382388-5534280
47: EXOC3 5:499264-525052
48: EXOC4 7:132588363-133401051
49: F11R 1:159231625-159275404
50: GNAI1 7:79602076-79686655
51: GNAI2 3:50239173-50271775
52: GNAI3 1:109892756-109938498
53: HCLS1 3:122832937-122862405
54: HRAS 11:522243-525572
55: IGSF5 21:40039204-40095893
56: INADL 1:61980737-62402180
57: JAM2 21:25933515-26009078
58: JAM3 11:133444030-133526846
59: KRAS 12:25249449-25295121
60: LLGL1 17:18069661-18088914
61: LLGL2 17:71033378-71082884
62: MAGI1 3:65317093-65999023
63: MAGI2 7:77486568-78920572
64: MAGI3 1:113734894-114030068
65: MLLT4 6:167970520-168115552
66: MPDZ 9:13095703-13240357
67: MPP5 14:66777774-66872288
68: MRAS 3:139549229-139604299
69: MRCL3 18:3237528-3246226
70: MRLC2 18:3252123-3268247
71: MYH1 17:10336353-10360684
72: MYH10 17:8318248-8474804
73: MYH11 16:15704495-15858369
74: MYH13 17:10145530-10217047
75: MYH14 19:55398697-55505610
76: MYH15 3:109581906-109730859
77: MYH2 17:10365198-10393704
78: MYH3 17:10472576-10500192
79: MYH4 17:10287332-10313601
80: MYH6 14:22921038-22946665
81: MYH7 14:22951789-22974690
82: MYH7B 20:33029094-33053901
83: MYH8 17:10234367-10265747
84: MYH9 22:35007273-35113958
85: MYL2 12:109833009-109842766
86: MYL5 4:657369-665816
87: MYL7 7:44144990-44147441
88: MYL8P :-
89: MYL9 20:34603311-34611640
90: MYLC2PL 7:101043475-101059118
91: MYLPF 16:30293622-30296813
92: NRAS 1:115048613-115102147
93: OCLN 5:68823875-68885887
94: PARD3 10:34438495-35144255
95: PARD6A 16:66252352-66254181
96: PARD6B 20:48781488-48803684
97: PARD6G 18:76016114-76106388
98: PPM1J 1:113054139-113059622
99: PPP2CA 5:133560047-133589849
100: PPP2CB 8:30762683-30789894
101: PPP2R1A 19:57385046-57421482
102: PPP2R1B 11:111102848-111142345
103: PPP2R2A 8:25098204-26284562
104: PPP2R2B 5:145949265-146415783
105: PPP2R2C 4:6373209-6525074
106: PPP2R3A 3:137167257-137349423
107: PPP2R3B X:214970-267627
108: PPP2R4 9:130913050-130951046
109: PRKCA 17:61729388-62237324
110: PRKCB1 16:23754823-24139358
111: PRKCD 3:53170263-53201771
112: PRKCE 2:45732547-46268632
113: PRKCG 19:59077279-59102713
114: PRKCH 14:60858186-61087443
115: PRKCI 3:171422919-171506458
116: PRKCQ 10:6509111-6662269
117: PRKCZ 1:1971769-2106694
118: PTEN 10:89612850-89721667
119: RAB13 1:152220751-152225452
120: RAB3B 1:52146216-52229024
121: RHOA 3:49371585-49424530
122: RRAS 19:54830364-54835212
123: RRAS2 11:14256889-14337289
124: SPTAN1 9:130354690-130435762
125: SRC 20:35406502-35467239
126: SYMPK 19:51010546-51058242
127: TJAP1 6:43553289-43582269
128: TJP1 15:27779656-27902010
129: TJP2 9:70956382-71059940
130: TJP3 19:3679374-3701810
131: VAPA 18:9903984-9949571
132: YES1 18:711747-802547
133: ZAK 2:173648811-173840986

Google Scholar

Recent Literature

Claudins in human cancer: A review.

Histol Histopathol. 2010 Jan; 25(1): 83-90
Ouban A, Ahmed AA

Claudins are Tight junction proteins that are critical for the sealing of cellular sheets and controlling paracellular ion flux. The claudin family of proteins is composed of at least 24 closely related transmembrane proteins, most of them are well characterized at the gene and protein levels. The claudins are present in variety of normal tissues, hyperplastic conditions, benign neoplasms, and cancers that exhibit epithelial differentiation. Loss of claudins expression has also been reported in several malignancies as well. Differential expression of various members of the claudins family in cancers can be used in confirming the histologic identity of certain cancers and excluding others. Examples include the use of immunohistochemical detection of claudins to differentiate between oncocytoma and chromophobe renal cell carcinoma, endometrial endometrioid carcinoma and seropapillary carcinoma, mesothelioma and metastatic adenocarcinoma, hepatocellular and biliary tract carcinomas, and between intestinal-type and diffuse-type gastric carcinoma. Expression of certain claudins can also be used as markers that can predict patient's prognosis. Thus, it seems that attempts to identify expression claudins in cancers are becoming increasingly useful in histologic diagnosis of tumors as well as means to assess patient's prognosis.

Expression of claudin-1, -3, -4, -5 and -7 proteins in low grade colorectal carcinoma of canines.

Histol Histopathol. 2010 Jan; 25(1): 55-62
Jakab C, Rusvai M, Gálfi P, Szabó Z, Szabára A, Kulka J

The aim of the present study was to characterise the expression pattern of claudin-1, -3, -4, -5 and -7 Tight junction proteins in canine normal colorectum and in the low-grade, tubulopapillary colorectal carcinoma in canines. Methods and results: The biopsy samples included 10 canine normal colorectal tissues and 20 canine low grade colorectal carcinomas (CLGCCs). The canine normal colorectal mucosa was negative for claudin-1. Claudin-1 was detected as a non-diffuse intense membrane labelling of neoplastic epithelial cells in low grade colorectal cancer in canines. Fifty five per cent of all tumours showed a weak cytoplasmic pattern of staining for claudin-1 protein. The normal colorectal mucosa showed diffuse punctate positivity for claudin-3. Claudin-3 was detected as an intense lateral membrane labelling of tumour cells in CLGCCs. Claudin-4 expression in surface and crypt epithelial cells of the intact colorectal mucosa in canines was punctate. Claudin-4 molecule was detected as a lateral membrane labelling of neoplastic cells in CLGCCs. The epithelium of the CLGCCs and the low grade colorectal carcinoma were negative for claudin-5. The surface and crypt epithlial cells of the canine normal colorectal mucosa showed a diffuse lateral membranous pattern of staining for claudin-7. Claudin-7 molecule was detected as an intense membrane labelling of neoplastic cells in CLGCCs. Seventy per cent of all tumours showed weak cytoplasmic positivity for claudin-7. Conclusion: Consequently, we hypothesize that claudin-1 plays a role in the progression of CLGCCs. Further functional studies are needed to clarify the biological role of the mislocalization of the claudin-1 molecule from cell membrane to the cytoplasm in CLGCCs. Lower claudin-4 expression suggests that reduced expression of claudin-4 molecule may lead to cellular disorientation, detachment and invasion of CLGCCs. Further functional studies are needed to clarify the biological role of overexpression and mislocalisation of claudin-7 in CLGCCs.

Wild-type measles virus infection of primary epithelial cells occurs via the basolateral surface without syncytium formation or release of infectious virus.

J Gen Virol. 2009 Nov 18;
Ludlow M, Rennick LJ, Sarlang S, Skibinski G, McQuaid S, Moore T, de Swart RL, Duprex WP

The lymphotropic and myelotropic nature of wild-type measles virus (wt-MV) is well recognised, with dendritic cells and lymphocytes expressing the MV receptor CD150 mediating systemic spread of the virus. Infection of respiratory epithelial cells has long been considered crucial for entry of MV into the body. However, the lack of detectable CD150 on these cells raises the issue of their importance in the pathogenesis of measles. Here we have utilised a combination of in vitro, ex vivo and in vivo model systems to characterise the susceptibility of epithelial cells to wt-MV of proven pathogenicity. Low numbers of MV-infected epithelial cells in close proximity to underlying infected lymphocytes or myeloid cells suggested infection via the basolateral side of the epithelium in the macaque model. In primary cultures of human bronchial epithelial cells foci of MV-infected cells were only observed following infection via the basolateral cell surface. The extent of infection in primary cells was enhanced both in vitro and in ex vivo cornea rim tissue by disrupting the integrity of the cells prior to the application of virus. This demonstrates that whilst epithelial cells may not be the primary target cells for wt-MV, areas of epithelium in which Tight junctions are disrupted can become infected using high multiplicities of infection. The low numbers of MV infected epithelial cells observed in vivo in conjunction with the absence of infectious virus release from infected primary cell cultures suggests that epithelial cells have a peripheral role in MV transmission.

Reversal of West Nile virus-induced blood-brain barrier disruption and Tight junction proteins degradation by matrix metalloproteinases inhibitor.

Virology. 2009 Nov 17;
Verma S, Kumar M, Gurjav U, Lum S, Nerurkar VR

Though compromised blood-brain barrier (BBB) is a pathological hallmark of WNV-associated neurological sequelae, underlying mechanisms are unclear. We characterized the expression of matrix metalloproteinases (MMP) in WNV-infected human brain microvascular endothelial cells (HBMVE) and human brain cortical astrocytes (HBCA), components of BBB and their role in BBB disruption. Expression of multiple MMPs was significantly induced in WNV-infected HBCA cells. Naïve HBMVE cells incubated with the supernatant from WNV-infected HBCA cells demonstrated loss of Tight junction proteins, which were rescued in the presence of MMP inhibitor, GM6001. Further, supernatant from WNV-infected HBCA cells compromised the in vitro BBB model integrity. Our data suggest astrocytes as one of the sources of MMP in the brain, which mediates BBB disruption allowing unrestricted entry of immune cells into the brain, thereby contributing to WNV neuropathogenesis. Because of the unavailability of WNV antivirals and vaccines, use of MMP inhibitors as an adjunct therapy to ameliorate WNV disease progression is warranted.

Influence of Hypercholesterolemia and Hypertension on the Integrity of the Blood-Brain Barrier in Rats.

Int J Neurosci. 2009; 119(10): 1881-1904
Kalayci R, Kaya M, Uzun H, Bilgic B, Ahishali B, Arican N, Elmas I, Küçük M

Hypercholesterolemia and/or hypertension impair endothelial function in peripheral vasculature; however, their impact on endothelial cells of brain microvessels is unclear. We investigated the effects of hypercholesterolemia on the integrity of the blood-brain barrier (BBB) and the activity of astrocytes during N(omega)-nitro-L-arginine methyl ester (L-NAME) hypertension followed by angiotensin (ANG) II. We found significant decreases in superoxide dismutase levels with all treatments except ANG II and L-NAME plus ANG II, and in catalase concentrations except ANG II and cholesterol plus L-NAME. Nitric oxide (NO) concentrations were significantly decreased by L-NAME but significantly increased by cholesterol. L-NAME-stimulated plasma malondialdehyde (MDA), Ox-LDL, and cholesterol levels were significantly augmented by cholesterol. Glutathione (GSH) levels significantly decreased, while MDA, TNF-alpha, and Ox-LDL levels significantly increased in cholesterol and/or L-NAME. The increase in BBB permeability by acute hypertension in hypercholesterolemic hypertensive animals was less than that observed in chronically hypertensive animals. Brain vessels of L-NAME-treated animals showed a considerable loss of immunoreactivity for Tight junction proteins, occludin, and ZO-1. Immunoreactivity for occludin and ZO-1 increased in cholesterol plus L-NAME and decreased in cholesterol. Glial fibrillary acidic protein (GFAP) immunoreactivity was seen in few astrocytes in the brain sections of L-NAME-treated animals, but increased in cholesterol plus L-NAME. Positive immunoreactivity for vascular endothelial growth factor (VEGF) was observed in cholesterol and cholesterol plus L-NAME plus ANG II. We suggest that hypercholesterolemia may affect BBB integrity through increasing the expression of Tight junction proteins and GFAP and leading to the production of VEGF, at least partly, via increased NO, TNF-alpha, and catalase in hypertensive conditions.

Tight junctions: A Barrier to the Initiation and Progression of Breast Cancer?

J Biomed Biotechnol. 2010; 2010: 460607
Brennan K, Offiah G, McSherry EA, Hopkins AM

Breast cancer is a complex and heterogeneous disease that arises from epithelial cells lining the breast ducts and lobules. Correct adhesion between adjacent epithelial cells is important in determining the normal structure and function of epithelial tissues, and there is accumulating evidence that dysregulated cell-cell adhesion is associated with many cancers. This review will focus on one cell-cell adhesion complex, the Tight junction (TJ), and summarize recent evidence that TJs may participate in breast cancer development or progression. We will first outline the protein composition of TJs and discuss the functions of the TJ complex. Secondly we will examine how alterations in these functions might facilitate breast cancer initiation or progression; by focussing on the regulatory influence of TJs on cell polarity, cell fate and cell migration. Finally we will outline how pharmacological targeting of TJ proteins may be useful in limiting breast cancer progression. Overall we hope to illustrate that the relationship between TJ alterations and breast cancer is a complex one; but that this area offers promise in uncovering fundamental mechanisms linked to breast cancer progression.

Dermatitis and aging-related barrier dysfunction in transgenic mice overexpressing an epidermal-targeted claudin 6 tail deletion mutant.

PLoS One. 2009; 4(11): e7814
Troy TC, Arabzadeh A, Larivière NM, Enikanolaiye A, Turksen K

The barrier function of the skin protects the mammalian body against infection, dehydration, UV irradiation and temperature fluctuation. Barrier function is reduced with the skin's intrinsic aging process, however the molecular mechanisms involved are unknown. We previously demonstrated that Claudin (Cldn)-containing Tight junctions (TJs) are essential in the development of the epidermis and that transgenic mice overexpressing Cldn6 in the suprabasal layers of the epidermis undergo a perturbed terminal differentiation program characterized in part by reduced barrier function. To dissect further the mechanisms by which Cldn6 acts during epithelial differentiation, we overexpressed a Cldn6 cytoplasmic tail deletion mutant in the suprabasal compartment of the transgenic mouse epidermis. Although there were no gross phenotypic abnormalities at birth, subtle epidermal anomalies were present that disappeared by one month of age, indicative of a robust injury response. However, with aging, epidermal changes with eventual chronic dermatitis appeared with a concomitant barrier dysfunction manifested in increased trans-epidermal water loss. Immunohistochemical analysis revealed aberrant suprabasal Cldn localization with marked down-regulation of Cldn1. Both the proliferative and terminal differentiation compartments were perturbed as evidenced by mislocalization of multiple epidermal markers. These results suggest that the normally robust injury response mechanism of the epidermis is lost in the aging Involucrin-Cldn6-CDelta196 transgenic epidermis, and provide a model for evaluation of aging-related skin changes.

Extracellular Mg(2+) regulates the Tight junctional localization of claudin-16 mediated by ERK-dependent phosphorylation.

Biochim Biophys Acta. 2009 Nov 12;
Ikari A, Kinjo K, Atomi K, Sasaki Y, Yamazaki Y, Sugatani J

Claudin-16 is involved in the paracellular reabsorption of Mg(2+) in the thick ascending limb of Henle. Little is known about the mechanism regulating the Tight junctional localization of claudin-16. Here, we examined the effect of Mg(2+) deprivation on the distribution and function of claudin-16 using Madin-Darby canine kidney (MDCK) cells expressing FLAG-tagged claudin-16. Mg(2+) deprivation inhibited the localization of claudin-16 at Tight junctions, but did not affect the localization of other claudins. Re-addition of Mg(2+) induced the Tight junctional localization of claudin-16, which was inhibited by U0126, a MEK inhibitor. Transepithelial permeability to Mg(2+) was also inhibited by U0126. The phosphorylation of ERK was reduced by Mg(2+) deprivation, and recovered by re-addition of Mg(2+). These results suggest that the MEK/ERK-dependent phosphorylation of claudin-16 affects the Tight junctional localization and function of claudin-16. Mg(2+) deprivation decreased the phosphothreonine levels of claudin-16. The phosphothreonine levels of T225A and T233A claudin-16 were decreased in the presence of Mg(2+) and these mutants were widely distributed in the plasma membrane. Furthermore, TER and transepithelial Mg(2+) permeability were decreased in the mutants. We suggest that the Tight junctional localization of claudin-16 requires a physiological Mg(2+) concentration and the phosphorylation of threonine residues via a MEK/ERK-dependent pathway.

Blood-brain interfaces and cerebral drug bioavailability.

Rev Neurol (Paris). 2009 Nov 12;
Ghersi-Egea JF, Mönkkönen KS, Schmitt C, Honnorat J, Fèvre-Montange M, Strazielle N

The low cerebral bioavailability of various drugs is a limiting factor in the treatment of neurological diseases. The restricted penetration of active compounds into the brain is the result of the same mechanisms that are central to the maintenance of brain extracellular fluid homeostasis, in particular from the strict control imposed on exchanges across the blood-brain interfaces. Direct drug entry into the brain parenchyma occurs across the cerebral microvessel endothelium that forms the blood-brain barrier. In addition, local drug concentration measurements and cerebral imaging have clearly shown that the choroid plexuses - the main site of the blood-cerebrospinal fluid (CSF) barrier - together with the CSF circulatory system also play a significant role in setting the cerebral bioavailability of drugs and contrast agents. The entry of water-soluble therapeutic compounds into the brain is impeded by the presence of Tight junctions that seal the cerebral endothelium and the choroidal epithelium. The cerebral penetration of many of the more lipid-soluble molecules is also restricted by various classes of efflux transporters that are differently distributed among both blood-brain interfaces, and comprise either multidrug resistance proteins of the ATP-binding cassette superfamily or transporters belonging to several solute carrier families. Expression of these transporters is regulated in various pathophysiological situations, such as epilepsy and inflammation, with pharmacological consequences that have yet to be clearly elucidated. As for brain tumour treatments, their efficacy may be affected not only by the intrinsic resistance of tumour cells, but also by endothelial efflux transporters which exert an even greater impact than the integrity of the endothelial Tight junctions. Relevant to paediatric neurological treatments, both blood-brain interfaces are known to develop a Tight phenotype very early on in postnatal development, but the developmental profile of efflux transporters still needs to be assessed in greater detail. Finally, the exact role of the ependyma and pia-glia limitans in controlling drug exchanges between brain parenchyma and CSF deserves further attention to allow more precise predictions of cerebral drug disposition and therapeutic efficacy.

EspM inhibits pedestal formation by EHEC and EPEC and disrupts the architecture of a polarized epithelial monolayer.

Cell Microbiol. 2009 Nov 12;
Simovitch M, Sason H, Cohen S, Zahavi EE, Melamed-Book N, Weiss A, Aroeti B, Rosenshine I

Summary Enterohaemorrhagic E. coli (EHEC) and enteropathogenic E. coli (EPEC) are enteropathogens characterized by their ability to induce the host cell to form actin-rich structures, termed pedestals. A type III secretion system (TTSS), through which the pathogens deliver effector proteins into infected host cells, is essential for their virulence and pedestal formation. EHEC encodes two similar effectors, EspM1 and EspM2, which activate the RhoA signaling pathway and induce the formation of stress fibers upon infection of host cells. We confirm these observations and in addition show that EspM inhibits the formation of actin pedestals. Moreover, we show that translocation of EspM into polarized epithelial cells induces dramatic changes in the Tight junction localization and in the morphology and architecture of infected polarized monolayers. These changes are manifested by altered localization of the Tight junctions and 'bulging out' morphology of the cells. Surprisingly, despite the dramatic changes in their architecture, the cells remained alive and the epithelial monolayer maintained a normal barrier function. Taken together, our results show that the EspM effectors inhibit pedestal formation and induce Tight junction mis-localization as well as dramatic changes in the architecture of the polarized monolayer.

Claudin-5 as a Novel Estrogen Target in Vascular Endothelium.

Arterioscler Thromb Vasc Biol. 2009 Nov 12;
Burek M, Arias-Loza PA, Roewer N, Förster CY

OBJECTIVE: Estrogens have multiple effects on vascular physiology and function. In the present study, we look for direct estrogen target genes within junctional proteins. METHODS AND RESULTS: We use murine endothelial cell lines of brain and heart origin, which express both subtypes of estrogen receptor, ERalpha and ERbeta. Treatment of these cells with 17beta-estradiol (E2) led to an increase in transendothelial electric resistance and a most prominent upregulation of the Tight junction protein claudin-5 expression. A significant increase of claudin-5 promoter activity, mRNA, and protein levels was detected in cells from both vascular beds. In protein lysates and in immunoreactions on brain sections from ovariectomized E2-treated mice, we noticed an increase in claudin-5 protein and mRNA content. Treatment of cells with a specific ERbeta agonist, diarylpropionitrile, revealed the same effect as E2 stimulation. Moreover, we detected significantly lower claudin-5 mRNA and protein content in ERbeta knockout mice. CONCLUSIONS: We describe claudin-5 as a novel estrogen target in vascular endothelium and show in vivo (brain endothelium) and in vitro (brain and heart endothelium) effects of estrogen on claudin-5 levels. The estrogen-induced increase in junctional protein levels may lead to an improvement in vascular structural integrity and barrier function of vascular endothelium.

Comparison of an animal model of arteriovenous malformation with human arteriovenous malformation.

J Clin Neurosci. 2009 Nov 10;
Tu J, Karunanayaka A, Windsor A, Stoodley MA

This study assessed the blood flow and histological changes of an animal model of arteriovenous malformation (AVM) over 84 days in 71 rats, and compared the histological findings to 17 specimens of human AVM. Carotid-jugular fistula blood flow positively correlated with time. The maximum flow rate occurred at 42 days, at which time the nidus was considered mature and was histologically similar to human AVMs. Morphological similarities between the model and human AVM vessels included heterogeneously thickened walls, splitting of the elastic lamina, thickened endothelial layers, endothelial cushions, lack of Tight junctions, loss of endothelial continuity, endothelial-subendothelial adherent junctions, and luminally directed filopodia. These findings support the theory that vascular changes in human AVMs are secondary to increased flow and provide a basis for using this model in studies of AVMs.

The skin's barrier.

G Ital Dermatol Venereol. 2009 Dec; 144(6): 689-700
Jensen JM, Proksch E

The skin provides an effective barrier between the organism and the environment, preventing the invasion of pathogens and fending off chemical and physical assaults, as well as the unregulated loss of water and solutes. In this review we provide an overview of several components of the physical barrier, as well as how barrier function is regulated and altered in association with dermatoses. The physical barrier localized primarily in the stratum corneum (SC) and consists of protein-enriched cells (corneocytes with cornified envelope and cytoskeletal elements, as well as corneodesmosomes) and lipid-enriched intercellular domains. The nucleated epidermis, with its Tight, gap and adherens junctions, additional desmosomes and cytoskeletal elements, also contributes to the barrier. Lipids are synthesized in the keratinocytes during epidermal differentiation and are then extruded into the extracellular domains, where they form lipid-enriched extracellular layers. The cornified cell envelope, a robust protein/lipid polymer structure, is located below the cytoplasmic membrane on the exterior of the corneocytes. Ceramides A and B, forming the backbone for the subsequent addition of free ceramides, free fatty acids and cholesterol in the SC, are covalently bound to cornified envelope proteins. Filaggrin is cross-linked to the cornified envelope and aggregates keratin filaments into macrofibrils. Cytokines, cAMP and calcium influence the formation and maintenance of barrier function. Changes in lipid composition and epidermal differentiation lead to a disturbed skin barrier, which allows the entry of environmental allergens, immunological reaction and inflammation in atopic dermatitis. A disturbed skin barrier is an important component in the pathogenesis of contact dermatitis, ichthyosis, psoriasis, and atopic dermatitis.

Clostridium perfringens enterotoxin interacts with claudins via electrostatic attraction.

J Biol Chem. 2009 Nov 10;
Kimura J, Abe H, Kamitani S, Toshima H, Fukui A, Miyake M, Kamata Y, Sugita-Konishi Y, Yamamoto S, Horiguchi Y

Clostridium perfringens enterotoxin (CPE), a causative agent of food poisoning, is a pore-forming toxin disrupting the selective permeability of the plasma membrane of target cells, resulting in cell death. We previously identified claudin as the cell surface receptor for CPE. Claudin, a component of Tight junctions, is a tetra-transmembrane protein and constitutes a large family of more than 20 members, not all of which serve as the receptor for CPE. The mechanism by which the toxin distinguishes the sensitive claudins is unknown. In this study, we localized the region of claudin responsible for interaction with CPE to the C-terminal part of the second extracellular loop, and found that the isoelectric point of this region in sensitive claudins was higher than insensitive claudins. Amino-acid substitutions to lower the pI resulted in reduced sensitivity to CPE among sensitive claudins, whereas substitutions to raise the pI endowed CPE-insensitive claudins with sensitivity. The steric structure of the claudin-binding domain of CPE reveals an acidic cleft surrounded by Tyr306, Tyr310, Tyr312, and Leu315, which were reported to be essential for interaction with the sensitive claudins. These results imply that an electrostatic attraction between the basic claudin region and the acidic CPE cleft is involved in their interaction.

CSD, BBB and MMP-9 elevations: animal experiments versus clinical phenomena in migraine.

Expert Rev Neurother. 2009 Nov; 9(11): 1595-614
Gupta VK

Cortical spreading depression (CSD) has been at the center stage of migraine pathophysiology for approximately six decades. Reanalysis of CSD reveals several major unbridgeable gaps in this experimental neurophysiologic concept for migraine. Key phenotypic and pharmacological features of migraine challenge the assumed pathophysiologic role of CSD. Detection of subclinical infarct-like white matter lesions (WMLs) in the brain of some migraine patients stimulated the concept of CSD-related BBB disruption. Raised plasma levels of matrix metalloproteinases (MMPs) in migraine patients in the headache phase, specifically MMP-9, suggested a pathogenetic role for MMP elevation in the development of both migraine attacks and WMLs. Migraine attacks with or without aura present a unique, profound and protracted vasodilatory challenge to the homeostatic systems of the brain. To accommodate the rather sudden increase in cerebral blood flow, the brain circulatory network must dilate and the BBB must expand considerably. MMPs can influence expansion of the extracellular matrix of the BBB and loosening of the intercellular Tight junctions between endothelial cells through proteolytic degradation during migrainous cerebrovascular dilatation. WMLs most probably reflect transient and discrete breakdown of the BBB consequent to sustained cerebral hyperperfusion rather than hypoperfusion. Systemic elevations of MMPs are not specific to migraine but are found in a variety of neurological and extra-neurological disorders. This perspective presents a conceptual dissociation between the effects of CSD on the brain of experimental animals and the clinical phenomena in migraine patients.

Role of PKCbetaII and PKCdelta in blood-brain barrier permeability during aglycemic hypoxia.

Neurosci Lett. 2009 Nov 10;
Kim YA, Park SL, Kim MY, Lee SH, Baik EJ, Moon CH, Jung YS

Blood-brain barrier (BBB) dysfunction contributes to the pathophysiology of cerebrovascular diseases such as stroke. In the present study, we investigated the role of PKC isoforms in aglycemic hypoxia-induced hyperpermeability using an in vitro model of the BBB consisting of mouse bEnd.3 cells. PKCbetaII and PKCdelta isoforms were activated during aglycemic hypoxia. CGP53353, a specific PKCbetaII inhibitor, significantly attenuated aglycemic hypoxia-induced BBB hyperpermeability and disruption of occludin and zonula occludens-1 (ZO-1), indicating a deleterious role of PKCbetaII in the regulation of BBB permeability during aglycemic hypoxia. Conversely, rottlerin, a specific PKCdelta inhibitor, exacerbated BBB hyperpermeability and Tight junction (TJ) disruption during aglycemic hypoxia, indicating a protective role of PKCdelta against aglycemic hypoxia-induced BBB hyperpermeability. Furthermore, disruption of TJ proteins during aglycemic hypoxia was attenuated by PKCbetaII DN and PKCdelta WT overexpression, and aggravated by PKCbetaII WT and PKCdelta DN overexpression. These results suggest that PKCbetaII and PKCdelta counter-regulate BBB permeability during aglycemic hypoxia.

The Structure of Tight junctions in Mouse Submandibular Gland.

Anat Rec (Hoboken). 2009 Nov 6;
Kikuchi K, Kawedia J, Menon AG, Hand AR

Salivary gland cells are joined by junctional complexes consisting of a Tight junction (TJ), zonula adherens and one or more desmosomes. TJs regulate paracellular permeability, maintain separate apical and basolateral membrane domains, and serve as signaling centers. We examined TJs of mouse submandibular glands (SMG) in thin sections and freeze-fracture replicas. TJs between acinar cells and between intercalated duct cells had 2-6 parallel strands on the protoplasmic fracture face, with occasional branches, interconnections and free ends, and corresponding grooves on the extracellular face. Granular duct cell TJs had 2-30 strands, a depth of

Joint involvement associated with inflammatory bowel disease.

Dig Dis. 2009; 27(4): 511-5
De Vos M

Joint involvement associated with inflammatory bowel disease (IBD) belongs to the concept of spondyloarthritis (SpA) and includes two types of arthritis: a peripheral arthritis characterized by the presence of pauciarticular asymmetrical arthritis affecting preferentially joints of lower extremities and an axial arthropathy including inflammatory back pain, sacroiliitis and ankylosing spondylitis (AS). Treatment of arthritis includes a short-term use of NSAIDs associated with optimized treatment of gut inflammation. Safety concerns mean that long-term treatment with NSAIDs is best avoided if possible. Salazopyrine can be recommended for treatment of peripheral arthritis. Methotrexate and azathioprine are generally ineffective. Finally, efficacy of anti-TNF therapy (infliximab and adalimumab) is well established. However, use of etanercept is not recommended because of the increased risk for intestinal disease relapse. Pathogenesis of gut-joint iteropathy is not elucidated. Both inflammations are Tightly related as suggested by human evidence of gut inflammation in patients with other forms of SpA and animal evidence of gut and joint inflammation in HLA-B27/human beta(2)-microglobulin transgenic rat model and TNF(DeltaARE) mice. Several clues for the linkage between gut and joint inflammation have been put forward including an altered recognition and handling of bacterial antigens, an aberrant trafficking of CD8+ T cells with an impaired T-helper type 1 cytokine profile and expression of aEb7 integrin, an altered trafficking of macrophages expressing CD163 and evidence of an increased angiogenesis. A transcriptome analysis of mucosal biopsies identified a set of 95 genes that are differentially expressed in both CD and SpA as compared with healthy controls suggesting common pathways. TNF plays a key role in the pathogenesis of various arthritic diseases and IBD. Mesenchymal/myofibroblast-like cells may represent the local primary targets of TNF in the induction of gut and joint pathology. Selective expression of TNFRI on these cells seems to be sufficient to orchestrate the complete development of SpA-related pathologies at least in TNF(DeltaARE) mice. Finally, genetic susceptibility is probably required to develop these pathologies. Genotyping of AS patients provided evidence for an important overlap between determinants of inherited predisposition to CD and AS. The best documented common association is with an IL-23R polymorphism, although the exact role remains unexplored. In addition, evidence suggests that a number of recently identified CD-susceptibility loci are associated with AS. Clinical, genetical, immunological and therapeutic evidence support the Tight junction between gut and joint inflammation in two linked diseases, IBD and SpA, belonging to the 'immune-mediated inflammatory diseases'.

Therapeutic options to modulate barrier defects in inflammatory bowel disease.

Dig Dis. 2009; 27(4): 450-4
Hering NA, Schulzke JD

In inflammatory bowel disease (IBD), epithelial barrier function is impaired contributing to diarrhea by a leak flux mechanism and perpetuating inflammation by an increased luminal antigen uptake. This barrier of the intestinal epithelium is composed of the apical enterocyte membrane and the epithelial Tight junction (TJ) and can be affected by TJ alterations, induction of epithelial apoptosis and appearance of gross lesions like erosions or ulcers as well as by accelerated transcytotic antigen uptake. TJ strands are reduced in Crohn's disease (CD) and strand breaks appear. Several of the 24 claudins are concerned in CD as e.g. claudin-2, -5 and -8. The epithelial apoptotic rate has also been shown to be elevated causing focal lesions. As far as regulation is concerned, Th1 cytokines like TNF-alpha and interferon-gamma are important for CD, while Th2 responses are dominated by interleukin (IL)-13 and TNF-alpha in ulcerative colitis (UC). IL-13 does stimulate epithelial apoptosis as well as upregulates claudin-2 in UC. Together with an IL-13-dependent restitution arrest, this may explain why ulcer lesions are seen already early in UC but only in advanced stages of CD. Luminal antigen uptake occurs via TJ discontinuities, epithelial gross lesions and endocytotically. Therapeutically, anti-inflammatory remedies as e.g. TNF-alpha antibodies are most effective in improving active IBD and in parallel repairing barrier function. Again, this is assumed to be due to reduced cytokine release in active IBD, as a result of immune cell apoptosis. However, other agents can also directly affect barrier function. Glutamine is discussed as a candidate for barrier therapy but has never been shown to have a direct barrier influence in CD, although it is an important metabolic fuel for enterocytes and has been shown to preserve barrier functions in laboratory models. Also, probiotics and TGF-beta and have beneficial effects in models, but no data exist on barrier repair in IBD. In contrast, zinc has been shown to improve barrier function in CD, although the inherent mechanisms are unknown. Finally, food components can strengthen the epithelial barrier as for example the flavonoid quercetin which has been shown to upregulate claudin-4 within the epithelial TJ.

Mechanisms and functional implications of intestinal barrier defects.

Dig Dis. 2009; 27(4): 443-9
Shen L, Su L, Turner JR

Intestinal epithelial barrier defects, or increased paracellular permeability, were first reported in patients with Crohn's disease (CD) over 25 years ago. Although increased permeability may herald relapse to active disease, suggesting that impaired barrier function may contribute to progression, limited understanding of the mechanisms that create barrier defects in CD has made it impossible to determine whether increased permeability is a cause or effect of disease. It is now clear that inflammatory cytokines trigger intestinal barrier defects acutely, by cytoskeletal contraction, or chronically, via modulation of Tight junction protein expression. Both mechanisms cause barrier dysfunction, but their effects on paracellular size and charge selectivity differ. The clinical ramifications of this distinction are not yet clear. Recent data using in vivo models demonstrate that cytoskeletally mediated barrier dysfunction is sufficient to activate innate and adaptive components of mucosal immunity. Consistent with the presence of increased permeability in some healthy first-degree relatives of CD patients, these barrier defects are insufficient to cause disease in the absence of other stimuli. However, cytoskeletally mediated barrier defects are sufficient to accelerate onset and increase severity of experimental inflammatory bowel disease. Thus, inflammatory cytokines can cause barrier defects and, conversely, barrier defects can activate the mucosal immune system. This raises the possibility that restoration of barrier function may be therapeutic in CD. Consistent with this hypothesis, emerging data indicate that inhibition of cytoskeletally mediated barrier dysfunction may be able to prevent disease progression. Barrier restoration may, therefore, represent a non-immunosuppressive approach to achieving or maintaining disease remission.